Toggle Main Menu Toggle Search

Open Access padlockePrints

Real-world data on spinal muscular atrophy in Spain: Insights from over 500 individuals in the CuidAME project

Lookup NU author(s): Sonia Segovia

Downloads


Licence

This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).


Abstract

BackgroundThe new treatment paradigm in Spinal Muscular Atrophy (SMA) has introduced novel phenotypes, changes in trajectories and clinical questions not fully addressed in clinical trials. To explore these challenges, several international initiatives have emerged. CuidAME was created as a nationwide clinical network in Spain designed to standardise SMA care, facilitate knowledge sharing, and capture data in a longitudinal comprehensive registry.ObjectiveEvaluating the usefulness of the CuidAME project to capture data in a real-world setting.MethodsThis multicentric cohort study includes individuals with SMA followed at participating hospitals. Clinical examinations and multidisciplinary assessments were performed during routine clinical visits. We present a cross-sectional analysis of the registry population.ResultsAs of February 2025, 543 participants from 25 hospitals were recruited: 12 were presymptomatic, 125 (23%) had SMA type 1, 208 (35%) type 2, 194 (38%) type 3, and 4 (<1%) type 4. Among the cohort, 91% (n = 495) had received at least one disease-modifier treatment, with 17 discontinuations. The registry included 5092 motor assessments, 1565 performed before treatment initiation.ConclusionsCuidAME is an academic, longitudinal, real-world data collection project that demonstrated a fast and effective model for implementation facilitating the standardization of clinical practices and outcome measures across Spain. By aligning with core dataset used in other registries and establishing multidisciplinary working groups, the initiative will contribute to sharing knowledge to advance SMA care and improve patient outcomes.


Publication metadata

Author(s): Puig-Ram C, Segovia S, Garcia-Uzquiano R, Nungo Garzon NC, Aragon-Gawinska K, Garcia Romero M, Exposito-Escudero JM, Carrera-Garcia L, Lopez-Lobato M, Paradas C, Gonzalez Mera L, Alvarez Molinero M, Gomez Andres D, Toro E, Fernandez Ramos JA, Grimalt MA, Toledo Bravo de Laguna L, Gonzalez Barrios D, Tizzano EF, Cattinari MG, Medina J, Calvo Medina R, Munell F, Sotoca J, Martinez-Salcedo E, Moreno Escribano A, Povedano Panades M, Fernandez-Garcia MA, Pitarch-Castellano I, Vazquez-Costa JF, Natera-de Benito D, Nascimento A

Publication type: Article

Publication status: Published

Journal: Journal of Neuromuscular Diseases

Year: 2025

Volume: 12

Issue: 6

Pages: 837-848

Print publication date: 01/11/2025

Online publication date: 28/07/2025

Acceptance date: 05/07/2025

Date deposited: 27/11/2025

ISSN (print): 2214-3599

ISSN (electronic): 2214-3602

Publisher: Sage

URL: https://doi.org/10.1177/22143602251361190

DOI: 10.1177/22143602251361190

Data Access Statement: Data will be available under reasonable request.

PubMed id: 40726133


Altmetrics

Altmetrics provided by Altmetric


Funding

Funder referenceFunder name
Biogen, Novartis and Roche

Share